Renal
Autosomal Dominant Polycystic Kidney Disease
Diagnosis (Pei-Ravine criteria), risk stratification (Mayo class), tolvaptan, cardiovascular & extra-renal complications.
Source: KDIGO 2024; UK Kidney Association 2024
Step 1 of ~4
info
Diagnosis
Pei-Ravine criteria for at-risk patients with positive family history:
• Age 15–39: ≥3 unilateral or bilateral cysts.
• Age 40–59: ≥2 cysts in each kidney.
• Age ≥60: ≥4 cysts in each kidney.
If no FH: ≥10 cysts each kidney + extra-renal features support.
Genetic testing if atypical or for transplant donor screening: PKD1 (85%), PKD2 (15%).
Related
Curated clinical cross-links plus same-class fallbacks.
Drugs
- Atorvastatin (CKD Cardiovascular Risk) · Cardiovascular Risk in CKD
- Icosapent Ethyl (Omega-3 — Cardiovascular Risk Reduction) · Omega-3 Fatty Acid (Purified EPA — Eicosapentaenoic Acid Ethyl Ester)
- Lidocaine (IV — Anaesthesia/ICU) · Local Anaesthetic / Antiarrhythmic (Class Ib)
- Amiodarone (IV — ICU/Peri-Arrest) · Antiarrhythmic (Class III)
- Lidocaine hydrochloride · Amide local anaesthetic / Class IB antiarrhythmic
- Tolvaptan · V2-Receptor Antagonist (Vasopressin Antagonist)
Pathways
- Hyperkalaemia Management · UK Kidney Association Guidelines 2020; NICE CKD Guidelines
- Rhabdomyolysis · Renal Association 2018; UpToDate 2024
- Hypocalcaemia (Adult) · Society for Endocrinology
- SIADH (Endocrine Perspective) · European Hyponatraemia Guidelines 2014
- Hepatorenal Syndrome · EASL 2018; ICA 2015
- Acute Kidney Injury (AKI) · KDIGO 2012 / NICE AKI 2019
Decision support only. Always apply local guidelines and clinical judgement.